Mirum Pharmaceuticals, Inc. , a leading rare disease company, today provided its preliminary and unaudited estimates for full-year 2025 net product sales, year-end cash balance, corporate updates and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback